Karen Wagner

Dr. Karen Wagner is a General Partner at Ysios Capital where she focuses on therapeutic investments. Dr. Wagner currently serves on the boards of AELIX Therapeutics, Vivet Therapeutics, Xeltis, and Minoryx Therapeutics.  Dr. Wagner holds a master’s degree in Molecular Biology and a Ph.D. in Cell Biology, both from the University of Konstanz, Germany.

Dr. Wagner has over 15 years of experience in business development and financing in the biotech/pharma sector working for companies such as F. Hoffmann-La Roche and GlycArt. Previously she was a Consultant in McKinsey & Company’s Global Healthcare Practice.